Joshua T. Kantrowitz

High dose D-serine in the treatment of schizophrenia

Joshua T. Kantrowitz, Anil K. Malhotra, Barbara A. Cornblatt et al. · Schizophrenia Research · 2010 · 247 citations · Full text

Medicine, Pharmacology, Psychiatry +12

D-serine for the treatment of negative symptoms in individuals at clinical high risk of schizophrenia: a pilot, double-blind, placebo-controlled, randomised parallel group mechanistic proof-of-concept trial

Joshua T. Kantrowitz, Scott W. Woods, Eva Petkova et al. · The Lancet Psychiatry · 2015 · 150 citations

Medicine, Pharmacology, Psychiatry +13

Neural mechanisms of mismatch negativity dysfunction in schizophrenia

Migyung Lee, Pejman Sehatpour, Matthew J. Hoptman et al. · Molecular Psychiatry · 2017 · 132 citations · Full text

Medicine, Neuroscience, Psychiatry +9

Improvement in mismatch negativity generation during d-serine treatment in schizophrenia: Correlation with symptoms

Joshua T. Kantrowitz, Michael L. Epstein, Migyung Lee et al. · Schizophrenia Research · 2017 · 129 citations

Medicine, Neuroscience, Psychiatry +10

A Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Tocilizumab, An Interleukin-6 Receptor Antibody, For Residual Symptoms in Schizophrenia

Ragy R. Girgis, Adam Ciarleglio, Tse Choo et al. · Neuropsychopharmacology · 2017 · 126 citations · Full text

Medicine, Immunology, Psychiatry +12